Growth | Page 84 of 99 | SpiritIndia.com

Health :: Pharmion enrolled first patient into Vidaza Patient Registry

Pharmion Corporation (Nasdaq: PHRM) announced today the enrollment of the first patient in AVIDA(TM), a registry for patients treated with Vidaza(R) (azacitidine for injectable suspension). Vidaza was approved in May 2004 for the treatment of all five French-American-British (FAB) subtypes of myelodysplastic syndromes (MDS): refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). Myelodysplastic syndromes are a serious and life-threatening group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells.

Cancer :: Stress hormones increase cancer growth

New research here suggests that hormones produced during periods of stress may increase the growth rate of a particularly nasty kind of cancer.

Multiple Sclerosis :: Increased sale of Copaxone drug for multiple sclerosis – Teva

COPAXONE? is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone? in the third quarter of 2006 grew by 15% as compared to the third quarter of 2005 and reached a record of $354 million.

Lymphoma :: Berlex Oncology Evaluating Combination Therapy for Non-Hodgkin’s Lymphoma

Berlex Oncology, a business unit of Berlex Laboratories, a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), today announced that a national clinical study is underway investigating a new approach to treating follicular B-cell lymphoma, a sub-type of non-Hodgkin?s lymphoma (NHL). NHL is the fifth most common form of cancer in the United States, with more than 56,000 new cases diagnosed each year. Follicular B-cell lymphoma is an indolent, or slow-growing, type of NHL that comprises approximately 30% of all diagnosed cases.

Hepatitis :: Glaxo eltrombopag improved platelet count in hepatitis C patients with thrombocytopenia

GlaxoSmithKline plc [NYSE:GSK, LSE:GSK] announced results from a global Phase II study of eltrombopag, an investigational non-peptide oral platelet growth factor. In this study of 74 hepatitis C patients with thrombocytopenia, (a condition where the blood has low platelet levels) more than 95% (p< 0.001) of patients treated with the highest dose of eltrombopag (75mg) had increased platelet counts. In addition, 71% - 91% of patients in all treatment groups were able to initiate antiviral therapy with pegylated interferon-α (IFN) and ribavirin, and 65% were able to be maintained on therapy.1 Full results from this Phase II study are being presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts.

Sleep :: Lonely adults get stress hormone boost next morning

A new study that takes a rare look at the physiological, social and emotional dynamics of day-to-day experiences in real-life settings shows that when older adults go to bed lonely, sad or overwhelmed, they have elevated levels of cortisol shortly after waking the next morning.

Health Care :: Nursing Spectrum becomes Gannett Healthcare Group

Gannett Co., Inc. announced that Nursing Spectrum, a wholly owned subsidiary of Gannett since 1995 and the nation?s largest print and electronic publisher of information for registered nurses, is now Gannett Healthcare Group. The company?s 12 regional nursing publications will continue to operate under their existing brand names, Nursing Spectrum in the Eastern United States, and NurseWeek in the Western United States, as they have for nearly 20 years.

Osteoporosis :: Calcium microspheres, bioactive ceramics for bone repair in osteoporosis, cancer

Rapid and guided healing of bones has moved a step closer with research by two biomedical engineering students who have found new ways to deliver bone growth enhancers directly to broken or weakened bones. Major ongoing research at Queensland University of Technology focuses on biodegradable materials that carry bone growth enhancing substances to encourage bones to heal quickly with much less intervention.

Allergy :: Key enzyme involved in allergic disease identified

A research team has identified a key enzyme responsible for triggering a chain of events that results in allergic reaction, according to new study findings published this week in Nature Immunology. The work by researchers from Virginia Commonwealth University, the Hospital for Special Surgery and Weill Cornell Medical College in New York sets the stage for development of new strategies and target therapies that control allergic disease – the sixth leading cause of chronic disease in the United States.

Breast Implants :: Stem cells from fat for breast reconstruction

Breast cancer survivors might one day avoid the prospect of invasive breast reconstruction surgery, opting instead for an approach that would involve using stem cells derived from their own fat, suggest University of Pittsburgh researchers who are studying the potential these cells may have for regenerating new breast tissue.